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Background: Chronic constipation is an important clinical condition which can result in 
serious discomfort and even require hospitalization. Powder and liquid lactulose are designated 
as clinically equivalent for the treatment of constipation, but there are significant differences 
in the taste, consistency, and portability of the products, which may affect patient compliance 
and therefore clinical outcome.
Aim: To evaluate patient preference between powder and liquid lactulose in terms of overall 
preference, taste, consistency, and portability, and safety in terms of adverse events.
Methods: Three sites randomized patients (total n = 50) to powder or liquid lactulose for seven 
days with crossover. Patient preference was assessed by a questionnaire, and the occurrence of 
adverse events was monitored.
Results: Of those expressing a preference, 44% and 57% more patients preferred the taste 
and consistency, respectively, of powder over liquid lactulose. More than six times as many 
patients preferred the portability of powder compared with liquid lactulose and, overall, 77% 
more patients preferred powder over liquid lactulose. There was no difference between treatment 
groups in terms of adverse events (P = 0.635).
Conclusions: More patients preferred powder compared with liquid lactulose and the products 
were equally safe. These findings may impact patient compliance, and therefore may affect 
clinical outcome.
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Introduction
Chronic constipation is an important clinical condition which can result in serious 
discomfort and decreased quality of life, and can even require hospitalization.1,2 Chronic 
constipation affects an estimated 15% of the North American population and has a wide 
range of underlying causes, from dehydration, to opioid use, to medical conditions such 
as endocrine, gastrointestinal, and neurologic disorders.2 Many pharmacologic, both 
over-the-counter and prescription, and herbal laxatives are available for the treatment of 
chronic constipation.2 However, a recent systematic review of the literature found that 
only lactulose and polyethylene glycol consistently and repeatedly loosened stools and 
thereby relieved constipation.3 Therefore, a prescription osmotic laxative like lactulose 
is a common therapeutic option for the treatment of chronic constipation.2,4
Lactulose is available in a dry, powder form (Kristalose®, lactose for oral solution) 
to be dissolved in water and a liquid/syrup form. While the products are designated as 
clinically equivalent, there are notable differences in the taste, consistency, and porta-
bility between the products. We hypothesized that these differences could result in a Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
154
Barish et al
difference in patient preference between powder and liquid 
lactulose. Increased patient preference can correlate with 
increased patient compliance. It is well known that decreased 
patient compliance results in poor patient outcomes.5,6 Addi-
tionally, a significant number of patients with hepatic enceph-
alopathy require daily treatment with large amounts of liquid 
lactulose (more than 50 mL per day) and these patients are 
often noncompliant because they are unable to ingest and/or 
keep down this large amount of lactulose syrup due to its taste 
and consistency.7–9 Therefore, we designed and conducted a 
study to determine whether patients prefer powder or liquid 
lactulose in terms of overall preference, taste, consistency, and 
portability. The safety of the products was also assessed.
Methods
Patients
This clinical trial was a prospective, randomized, open-label, 
multicenter, seven-day, crossover study. Patients seen at the 
outpatient clinics of Wake Research Associates (Raleigh, 
NC, USA), Rapid Medical Research (Cleveland, OH, USA), 
and Arya Gastroenterology (Brooklyn, NY, USA) with a 
recent diagnosis of chronic constipation (within the last 
90 days) were eligible for enrollment in this study. Patients 
provided written informed consent before enrollment, and 
the study protocol was approved by the Western Institutional 
Review Board and the study was registered on ClinicalTrials.
gov (NCT00712543). Inclusion criteria included a recent 
diagnosis of chronic constipation (within the last 90 days). 
Exclusion criteria included patients with galactosemia 
(galactose-sensitive diet), patients younger than 18 years 
of age, patients currently on lactulose therapy, and patients 
unable to understand the requirements of the study or 
unwilling to provide written informed consent and agreement 
to abide by the study restrictions.
study randomization,  
design, and medications
Patients were randomized in a 1:1 ratio to receive powder 
or liquid lactulose first for seven days (dose determined by 
treating physician, range for powder = 10–20 g/day, range 
for liquid = 15–30 mL/day), and then the patients crossed 
over to the alternative treatment for the following seven days 
(dose again determined by treating physician, Figure 1). 
Patients returned to the study site on study day 6 or 7 to pick 
up the formulation of lactulose which they were scheduled to 
cross over to for the remainder of the study (Figure 1). Sealed 
envelopes containing the patient randomization scheme were 
provided to the study sites. Powder lactulose   (Kristalose®, 
 Study day
Screening/Baseline visit 
(Pre-treatment period) 
Pick up Drug 2 
Study completion visit 
(Post-treatment period) 
Total patients 
enrolled N = 50 
Powder  lactulose 
10–20 g/day 
 n = 27 
Liquid lactulose 
15–30 mL/day 
 n = 23 
Powder  lactulose 
10–20 g/day 
 n = 23 
Liquid lactulose 
15–30 mL/day 
 n = 27 
  Day  
 1–7 
Day 
 8–14 
012345 67 9 81 01 11 21 31 4
Drug 1D rug 2
15*
Figure 1 study randomization and design.
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Cumberland Pharmaceuticals Inc., Nashville, TN, USA) was 
  provided in 10 g pouches and liquid lactulose syrup (  Generlac, 
Morton Grove Pharmaceuticals Inc., Morton Grove, IL, USA) 
was provided in a 473 mL (pint) bottle. Patient preference was 
assessed on a questionnaire administered by study staff in the 
days following completion of the study. Both treatment groups 
received both drugs in a crossover design (drug sequence 
determined by randomization), and then preference was evalu-
ated after patients had been exposed to both treatments in this 
prospective study. The study sponsor developed the patient 
questionnaire and two versions were developed and utilized 
equally to avoid bias. One version of the questionnaire listed 
powder first as an answer selection for all of the questions, 
while the other listed liquid first as an answer selection for all 
of the questions. Each question on the questionnaire had three 
possible answers, ie, liquid, powder, or no preference. Spanish 
translations of the questionnaire and other study documents 
were made available at the request of the Brooklyn, NY site. 
Upon completion of the study, patients were allowed a seven-
day window (total study duration including questionnaire 
visit = 21 days) to return to the study site and complete the 
questionnaire, and adverse events were monitored throughout 
the entire study period (Figure 1).
study objectives
The primary objective of this study was to determine overall 
patient preference for the powder or liquid form of lactulose. 
Secondary objectives included determination of patient pref-
erence for the powder or liquid form of lactulose in terms of 
taste, consistency, and portability, as well as safety in terms 
of the incidence of adverse events.
statistical analysis
The responses on the questionnaire were summarized for each 
treatment sequence and then combined for an overall assess-
ment. For each question, the Mainland–Gart test was used 
to test whether subjects preferred one product over the other 
product. The Mainland–Gart test excludes patients who show 
“no preference” (P value 1, Table 2).10,11 A second analysis 
method was performed for each question on the question-
naire using the Prescott test to determine whether subjects 
preferred one product over the other product.12 The Prescott 
test includes patients who show “no preference” (P value 2, 
Table 2).12 The Mainland–Gart test and the Prescott test were 
performed side by side to assess the robustness of the data, 
more specifically in terms of how the inclusion of the subjects 
who had “no preference” affected the inference regarding 
which drug is preferred. Adverse events were   summarized 
based on the treatment (powder or liquid lactulose) the subject 
was taking at the time of the onset of the event (Table 3). 
Fisher’s Exact test was used to test whether there was a sig-
nificant difference in the number of adverse events between 
the two treatment groups (Table 3).
Results
Patient characteristics
A total of 50 patients with a recent diagnosis of chronic 
constipation were enrolled in this study. Twenty-three 
of the 50 patients received powder lactulose for the first 
seven days followed by liquid lactulose on the following 
seven days, while 27 of the 50 patients first received liquid 
lactulose for seven days followed by powder lactulose on 
the following seven days. Two of the patients failed to 
return to the study site to complete the questionnaire, but 
limited safety data were still available for these patients. 
The study group demographics are shown in Table 1. The 
mean   (standard deviation, SD) age of the patients was 49 (15) 
years, with a female-to-male ratio of 2.85 to 1 (Table 1). 
The majority of the patients were African-American, with 
Caucasians, Hispanics, and Asians making up smaller por-
tions of the study population (Table 1). The mean height of 
the study population was 167 (10.4) cm and the mean weight 
was 87.4 (21.0) kg (Table 1).
Of the 50 patients enrolled in the study, seven protocol 
deviations were recorded in six (12%) patients. Protocol 
Table 1 Patient demographics
Age (years)
 n 50
  Mean (sD) 48.61 (14.95)
  Median 48.5
  Minimum, maximum 20.75, 81.17
Gender
  Male 13 (26%)
  Female 37 (74%)
race
  Caucasian 13 (26%)
  African-American 26 (52%)
  hispanic 9 (18%)
  Asian 1 (2%)
  Other 1 (2%)
height (cm)
  Mean (sD) 167.18 (10.41)
  Median 165.95
  Minimum, maximum 142.2, 191.4
Weight (kg)
  Mean (sD) 87.42 (20.98)
  Median 81.55
  Minimum, maximum 54.4, 142.8
Abbreviation: sD, standard deviation.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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deviations included patients who received the study drug 
outside the treatment window or patients who made a clinical 
visit on the incorrect day.
Preference data
Of the 48 patients for whom preference data were available, 
no significant difference in terms of overall preference, 
taste, or consistency between powder and liquid lactulose 
was found, likely due to the small sample size (Table 2 and 
Figure 2). However, significantly more patients preferred 
powder lactulose in terms of portability (P , 0.001, 
Table 2 and Figure 2). In addition, of those patients 
expressing a preference, 23/39 (59%) and 22/36 (61%) 
patients preferred the taste and consistency of powder 
over liquid lactulose, respectively, and overall 23/36 
(64%) patients preferred powder over liquid lactulose (not 
significant, Table 2 and Figure 3). A comparison of these 
patient ratios revealed that of those patients expressing a   
Table 2 Patient preference data in terms of overall preference 
and preference of taste, consistency, and portability
Which product  
would you rather 
take?
Randomization sequence
Powder/liquid 
(n = 23)
Liquid/powder 
(n = 27)
Overall 
(n = 50)
Powder 12 (52%) 11 (41%) 23 (46%)
Liquid 7 (30%) 6 (22%) 13 (26%)
no preference 4 (17%) 8 (30%) 12 (24%)
Missing 0 2 (7%) 2 (4%)
P valuea 0.181
P valueb 0.153
Which product  
did you prefer  
in terms of taste?
Powder 12 (52%) 11 (41%) 23 (46%)
Liquid 7 (30%) 9 (33%) 16 (32%)
no preference 4 (17%) 5 (19%) 9 (18%)
Missing 0 2 (7%) 2 (4%)
P valuea 0.341
P valueb 0.560
Which product did  
you prefer in terms  
of consistency?
Powder 11 (48%) 11 (41%) 22 (44%)
Liquid 7 (30%) 7 (26%) 14 (28%)
no preference 5 (22%) 7 (26%) 12 (24%)
Missing 0 2 (7%) 2 (4%)
P valuea 0.318
P valueb 0.435
Which product did  
you prefer in terms  
of portability?
Powder 17 (74%) 16 (59%) 33 (66%)
Liquid 1 (4%) 4 (15%) 5 (10%)
no preference 5 (22%) 5 (19%) 10 (20%)
Missing 0 2 (7%) 2 (4%)
P valuea ,0.001
P valueb ,0.001
Notes:  aP value is based on a Mainland–Gart test, including only patients who 
recorded a preference (preferred Kristalose®, preferred lactulose); bP value is based 
on a Prescott test, including only patients who recorded a response (preferred 
Kristalose, preferred lactulose, no preference).
Table 3 Adverse events experienced by patients while taking 
liquid or powder lactulose
System organ class 
(preferred term)
Liquid 
(n = 50)
Powder 
(n = 50)
Any treatment-emergent event 10 (20%) 13 (26%)
 P  value 0.635
Gastrointestinal disorders 9 (18%) 12 (24%)
 P  value 0.624
  Flatulence 6 (12%) 7 (14%)
 P  value .0.999
  Abdominal distension 2 (4%) 3 (6%)
 P  value .0.999
  Diarrhea 1 (2%) 2 (4%)
 P  value . 0.999
  Abdominal pain upper 1 (2%) 1 (2%)
 P  value .0.999
  nausea 1 (2%) 1 (2%)
 P  value .0.999
  Abdominal pain lower 0 1 (2%)
 P  value .0.999
  Constipation 1 (2%) 0
 P  value .0.999
  Vomiting 0 1 (2%)
 P  value .0.999
Musculoskeletal and connective  
tissue disorders
0 2 (4%)
 P  value 0.495
  Muscle spasms 0 2 (4%)
 P  value 0.495
nervous system disorders 2 (4%) 0
 P  value 0.495
  Dizziness 1 (2%) 0
 P  value .0.999
  headache 1 (2%) 0
 P  value .0.999
respiratory, thoracic,  
and mediastinal disorders
2 (4%) 0
 P  value 0.495
  Pharyngolaryngeal pain 2 (4%) 0
 P  value 0.495
  Cough 1 (2%) 0
 P  value .0.999
Metabolism and nutrition 
disorders
1 (2%) 0
 P  value .0.999
  hyperglycemia 1 (2%) 0
 P  value .0.999
Uncoded 0 1 (2%)
 P  value .0.999
  Menstrual cramps 0 1 (2%)
 P  value .0.999Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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preference, 44% and 57% more patients preferred the taste 
and consistency of powder over liquid lactulose, respec-
tively, and overall 77% more patients preferred powder 
over liquid lactulose. In addition, more than six times as 
many patients whom expressed a preference preferred the 
portability of powder over liquid lactulose (P , 0.001, 
Table 2 and Figure 3).
Safety data
Adverse events were of mild to moderate intensity, and 
ranged from gastrointestinal disorders, such as flatulence 
and diarrhea, to muscle spasms and pharyngolaryngeal pain. 
There were no statistically significant differences between 
treatment groups in terms of adverse event occurrence, 
given that 13 (26%) patients experienced 21 adverse events 
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Figure 2 Preference data in terms of overall preference and preference of taste, consistency, and portability in all patients (includes those who expressed ‘no preference’).
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Figure 3 Preference data in terms of overall preference and preference of taste, consistency, and portability in only the patients who expressed a preference for powder 
or liquid lactulose.Clinical and Experimental Gastroenterology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-and-experimental-gastroenterology-journal
Clinical and Experimental Gastroenterology is an international, peer-
reviewed, open access journal, publishing all aspects of gastroenterology 
in the clinic and laboratory, including: Pathology, pathophysiology 
of gastrointestinal disease; Investigation and treatment of gastointes-
tinal disease; Pharmacology of drugs used in the alimentary tract; 
Immunology/genetics/genomics related to gastrointestinal disease.   
This journal is indexed on CAS. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system. Visit http://www.dovepress.com/testimonials.php to read real 
quotes from published authors.
Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
158
Barish et al
while taking powder lactulose and 10 (20%) patients 
experienced 18 adverse events while taking liquid lactulose 
(P = 0.635, for the number of patients experiencing one or 
more adverse events, Table 3). Additionally, there were no 
significant differences between treatment groups for any 
adverse event subtype (Table 3).
Discussion
The main objective of this study was to determine whether 
patients prefer to take powder or liquid lactulose. Although 
the study was somewhat underpowered, the data showed 
a numeric difference in favor of powder lactulose being 
preferred considerably more than liquid lactulose in 
terms of overall preference and preference of taste and 
consistency. In addition, significantly more patients pre-
ferred the portability of powder lactulose compared with 
liquid lactulose. Powder and liquid lactulose were also 
found to be equally safe, because there was not a significant 
difference in the incidence of adverse events between 
treatment groups.
This study had several limitations. As was already 
mentioned, the study was underpowered due to the small 
sample size and due to three possible outcomes on the 
preference questionnaire (preference of powder, prefer-
ence of liquid, or no preference). In addition, the study was 
limited geographically to the eastern US, and a broader 
involvement of sites may have affected the outcome of the 
study. The study may have also been too short in duration, 
as a longer dosing regimen may have altered the outcome 
of the study. Patients may have also had a pre-existing 
preference for one formulation or the other based on being 
previously treated with either or both of the products, but 
this was not factored into the study. Lastly, this study did 
not use standardized dosing, because the study doses were 
instead determined by the treating physician. For example, 
one patient may have been prescribed 20 g of powder 
lactulose per day compared with 15 mL of liquid lactulose 
(10 g powder lactulose = 15 mL liquid lactulose), which 
may have affected patient preference.
Overall, more patients with chronic constipation preferred 
powder lactulose compared with liquid lactulose and the 
products were equally safe. Most importantly, these findings 
may impact patient compliance, and therefore may effect 
clinical outcome and thereby determine whether additional 
medical attention may be required.
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